Discover the D.A.T.A. method and its utility in enrolling diverse representative patient populations in rare disease clinical trials.
- SCOPE Takeaways On Inclusion And Real Patient-Centricity
- My SCOPE Groundhog Day Experience
- How To Operationalize AI-Enabled eTMF Systems Under The EU AI Act (Part 2)
- How AI-Enabled eTMF Systems Are Impacted By The EU AI Act (Part 1)
- These Four Things Are Helping Minovia Therapeutics' Rare Disease Trials
- Heard At SCOPE: Pharma Wants ROI For Patient Data Return, Diverse Enrollment
- What ChatGPT Ads Will Really Mean For Clinical Trials
GUEST COLUMNISTS
-
What ChatGPT Ads Will Really Mean For Clinical Trials
AI health assistants may be used to surface clinical trials earlier in patient journeys, and advertising inside conversational AI is best understood as the next logical step in that same progression.
-
The FDA Calls For Culturally-Informed Research, But What Do We Understand About The Sikh Community?
Despite the size and visibility of the community — and the call for diverse patient research — there remains a gap in available health data specific to the Sikh community in the U.S.
-
The Key Role Of Clinical Supply Teams In Patient Centricity Efforts
Clinical supply decisions shape patient access, safety, and trial success. From logistics to procurement, patient-centric supply can accelerate therapies or quietly delay them.
-
Pharma Procurement Can Make Or Break Startups: Let's Help Mature Our Future Partners To Secure Innovation
To secure long-term innovation, Ascendis Pharma's Ivanna Rosendal suggests pharma companies should help startup companies through their growing pains.
-
Becoming A Backbone Therapy: Lessons Learned With Actuate Therapeutics
CEO Dan Schmitt discusses the pursuit of a backbone therapy and how Actuate's current and planned trials are structured to confirm that potential.
-
Building Patient Trust In Research Through Connection Driven-Transparency
The question is not whether trust matters but how industry, sponsors, and investigators can bridge the trust gap to drive patient participation.
-
How To Lead A Moonshot Collaboration: Lessons From Over A Decade Of Competitors Working Together
TransCelerate BioPharma's Andy Lee and Janice Change share the lessons they learned bringing disparate voices together for a united purpose.
-
Patient Trust In Pharma Is Low; Here's How To Rebuild It
CISCRP's Annick de Bruin and Shalome Sine provide strategies for building patient trust based on the findings from their Perceptions & Insights Study.
CLINICAL TRIAL WHITE PAPERS
-
Blueprint For Early Phase Clinical Pharmacology Studies In Dermatology
Explore the landscape of dermatological drug development through a comprehensive framework for rational early-phase dermatological trials, centered around five foundational pillars.
-
Digital Endpoint Resource Guide: Sleep Disorders12/10/2025
Sensor-driven digital endpoints track sleep patterns and disruptions, standardize trial outcomes, and enable remote monitoring that reduces patient burden while improving treatment-response insights.
-
What the FDA Looks For In Global Development Programs Today1/16/2026
Mastering the complexities of multi-regional clinical trials requires aligning global data with evolving regulatory expectations to ensure treatment consistency and successful drug approval.
-
How Can Digital Measures Advance Heart Failure Research?2/27/2024
Wearable DHTs offer a less burdensome means of collecting data on physical activity, mobility, and sleep patterns, all of which are crucial indicators in heart failure management.
-
The Impact Of High Inflation And The Great Resignation On Clinical Site Budgeting10/30/2024
The twin pressures of inflation and attrition prolong negotiations between sponsors and clinical sites, stalling drug development. Sponsors need up-to-date, reliable benchmark data to negotiate fair market value budgets.
-
Overcoming Issues Of Non-Enrolling Sites In Clinical Trials1/14/2025
Explore the challenges of non-enrolling sites in clinical trials, focusing on the benefits of leveraging artificial intelligence (AI) and machine learning (ML) in addressing those issues.
CLINICAL TRIAL APP NOTES & CASE STUDIES
-
The Perfect Solution For Recruitment, Retention, And ROI8/15/2024
See how Citeline Connect was deployed to advance enrollment six months ahead of schedule for a sponsor’s Phase IV atopic dermatitis trial and build a community of engaged patients.
-
DTx Company Leverages Real-World Evidence Platform In Registry Study8/19/2024
Discover how Castor’s eClinical system enabled a groundbreaking study in behavioral disorder treatment to collect Real-World Evidence (RWE) to support product research and claims.
-
How Optina Diagnostics Used EDC In Earlier Disease Detection5/15/2024
Understand how Optina Diagnostics streamlined operations and achieved significant milestones by leveraging Castor's tools in its effort to revolutionize the diagnostic process for Alzheimer’s.
-
How Cara Therapeutics Increased Compliance And Reduced Study Team Burden7/31/2025
Delve into the partnership that helped Cara Therapeutics achieve a significant milestone in their clinical research efforts to transform the lives of chronic pruritus patients.
-
Faster Trial Planning and Site Selection4/15/2025
Address the challenges of identifying the most suitable trial sites and investigators while optimizing feasibility planning, reducing screen failure rates, and improving patient retention.
-
Driving A High-Adherence LTFU Trial Without An EDC10/29/2025
Discover how our partnership with a client was able to deliver a ten-year long-term follow-up (LTFU) trial that delivered an over 90% adherence rate while keeping trial costs low by not using an EDC.
NEWSLETTER ARCHIVE
- 02.16.26 -- Heard At SCOPE: Pharma Wants ROI For Patient Data Return, Diverse Enrollment
- 02.14.26 -- Best Of January
- 02.13.26 -- Continuous Evidence Generation Remains Critical To Vaccine Development
- 02.13.26 -- Find A Consulting Partner To Boost Your Clinical Trials
- 02.12.26 -- What CROs Do Right Isn't Always Obvious To Research Sites
RECRUITMENT AND DIVERSITY
This section includes some helpful resources regarding patient recruitment and diversity in clinical trials, including this link to the FDA's guidance on diversity action plans.
-
Discover the D.A.T.A. method and its utility in enrolling diverse representative patient populations in rare disease clinical trials.
-
On December 15, 2025, the FDA finalized its guidance Enhancing Participation in Clinical Trials, formally updating expectations for enrollment and trial design. Here's what you can do now.
-
AI health assistants may be used to surface clinical trials earlier in patient journeys, and advertising inside conversational AI is best understood as the next logical step in that same progression.
FOCUS ON PATIENTS
-
Discover the D.A.T.A. method and its utility in enrolling diverse representative patient populations in rare disease clinical trials.
-
Twice I heard “ROI is the elephant in the room.” Two different panel discussions, two different tracks.
-
Despite the size and visibility of the community — and the call for diverse patient research — there remains a gap in available health data specific to the Sikh community in the U.S.